Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches

Infect Dis Clin North Am. 2020 Dec;34(4):849-861. doi: 10.1016/j.idc.2020.04.003. Epub 2020 Sep 30.

Abstract

Vancomycin and daptomycin are options for the initial treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia.

Keywords: Bacteremia; Ceftaroline; Daptomycin; Endocarditis; MRSA; Methicillin; Staphylococcus aureus; Vancomycin.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy
  • Bacteremia / microbiology*
  • Ceftaroline
  • Cephalosporins / pharmacology
  • Cephalosporins / therapeutic use
  • Clinical Trials as Topic
  • Daptomycin / pharmacology
  • Daptomycin / therapeutic use
  • Humans
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Microbial Sensitivity Tests
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Vancomycin / pharmacology
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Vancomycin
  • Daptomycin